(460g) Viscosity of Protein Solutions
Improvements in genetic engineering, development, processing, and manufacturing of biotherapeutics have made monoclonal antibodies (mAbs) a leading source of new pharmaceuticals. Currently, there are more than 30 BsAbs in clinical trials for autoimmune, oncology, or chronic inflammatory indications. Solution rheology is one key physical property that is often screened during early development and late stage discovery, since downstream processing and manufacturing steps (such as filtration, pumping and filling), as well as final product administration, are substantially affected by solution viscosity. In this talk, I will focus on the relationship between antibody solution viscosity and molecular interactions of similar mono- and bispecific molecules. Viscosity and protein interactions are measured using multiple particle tracking (MPT) microrheology and light scattering (LS), respectively. The concentration-, temperature-, and composition-dependence of the solution viscosities will be discussed.